whatpeptidestostack
← Compound library
PT-141 and Tirzepatide
Co-administeredA registered trial has begun giving both compounds to the same subjects. No result has been reported, so the pairing is a registration, not a finding.
How the two mechanisms relate
Synergy. PT-141 is a melanocortin-receptor agonist and Tirzepatide a dual-incretin agonist, two distinct receptor pathways, and the two were co-administered in a registered study.
This reading describes mechanism and is editorial. The grade above is the published record.
The compounds
PT-141
A melanocortin receptor agonist with one approved use and a disputed effect size. It has one pairing in this atlas from a study that gave two compounds to the same subjects.
Full profile, dosing and safety →Tirzepatide
An approved dual-incretin medicine with strong human evidence. This atlas covers it for research context only; its affiliate partner has discontinued it, so no buy path is shown.
Full profile, dosing and safety →